Literature DB >> 11091275

Renal cytokine responses in acute Escherichia coli pyelonephritis in IL-6-deficient mice.

A Khalil1, K Tullus, T Bartfai, M Bakhiet, G Jaremko, A Brauner.   

Abstract

The aim of this study was to investigate the influence of IL-6 on mortality, bacterial growth and cytokine expression in experimental acute pyelonephritis. Female IL-6-deficient mice and their wild-type counterparts, 8-10 weeks old, were infected with Escherichia coli CFT 073 or injected with NaCl 0.9% (w/v) via the urethra and thereafter obstructed for 6 h. Animals were killed at 48 h, 6 days or 8 weeks and cytokine and bacterial renal levels were assessed at each time point. We found that IL-6-deficient mice had increased mortality and extensive renal bacterial growth on day 6, compared with wild-type mice (P < 0.05) and the histopathological changes were generally more severe and widespread in the IL-6-deficient mice. Peak mRNA expression of IL-1beta, IL-4, IL-10, IL-12 and interferon-gamma (IFN-gamma) occurred 48 h after infection in both IL-6 knock out and wild-type mice. Transforming growth factor-beta (TGF-beta) levels also peaked at 48 h in E. coli-infected wild-type mice, while in the IL-6-deficient strain both TGF-beta mRNA and protein levels were significantly lower at 48 h than wild-type levels (P < 0.0008 and P < 0.03, respectively) and remained stationary throughout the study period. Animals injected with NaCl 0.9% (w/v) displayed a similar decrease in TGF-beta expression (P < 0.02). When splenocytes from the IL-6-deficient mice were incubated with murine recombinant IL-6, TGF-beta levels increased to those of wild-type mice. No increase was observed when splenocytes from wild-type mice were incubated with the same doses of rIL-6. We therefore conclude that IL-6 plays an important role in bacterial clearance and directly influences the TGF-beta levels in experimental acute pyelonephritis. We also demonstrate that urethral obstruction per se induces an increase in TGF-beta the magnitude of which is decreased in IL-6-deficient mice.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11091275      PMCID: PMC1905778          DOI: 10.1046/j.1365-2249.2000.01377.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  32 in total

1.  The human cationic antimicrobial protein (hCAP18), a peptide antibiotic, is widely expressed in human squamous epithelia and colocalizes with interleukin-6.

Authors:  M Frohm Nilsson; B Sandstedt; O Sørensen; G Weber; N Borregaard; M Ståhle-Bäckdahl
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

Review 2.  Interleukin-6 and its receptor: a paradigm for cytokines.

Authors:  T Kishimoto; S Akira; T Taga
Journal:  Science       Date:  1992-10-23       Impact factor: 47.728

3.  IL-6 and IL-1 enhance the accessory activity of human blood monocytes during differentiation to macrophages.

Authors:  J Ruppert; J H Peters
Journal:  J Immunol       Date:  1991-01-01       Impact factor: 5.422

Review 4.  Interleukin-6: an overview.

Authors:  J Van Snick
Journal:  Annu Rev Immunol       Date:  1990       Impact factor: 28.527

5.  IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice.

Authors:  D Aderka; J M Le; J Vilcek
Journal:  J Immunol       Date:  1989-12-01       Impact factor: 5.422

6.  Local cytokine production in a murine model of Escherichia coli pyelonephritis.

Authors:  H S Rugo; P O'Hanley; A G Bishop; M K Pearce; J S Abrams; M Howard; A O'Garra
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

7.  Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF.

Authors:  R Schindler; J Mancilla; S Endres; R Ghorbani; S C Clark; C A Dinarello
Journal:  Blood       Date:  1990-01-01       Impact factor: 22.113

8.  CD8 is critically involved in lymphocyte activation by a T. brucei brucei-released molecule.

Authors:  T Olsson; M Bakhiet; B Höjeberg; A Ljungdahl; C Edlund; G Andersson; H P Ekre; W P Fung-Leung; T Mak; H Wigzell; U Fiszer; K Kristensson
Journal:  Cell       Date:  1993-03-12       Impact factor: 41.582

9.  Recombinant interleukin-6 protects mice against experimental bacterial infection.

Authors:  Z Liu; R J Simpson; C Cheers
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

Review 10.  Some recent advances in the chemistry and biology of transforming growth factor-beta.

Authors:  M B Sporn; A B Roberts; L M Wakefield; B de Crombrugghe
Journal:  J Cell Biol       Date:  1987-09       Impact factor: 10.539

View more
  14 in total

1.  Dose-dependent induction of IL-6 by plant-derived proteases in vitro.

Authors:  B Rose; C Herder; H Löffler; G Meierhoff; N C Schloot; M Walz; S Martin
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

2.  Association of interleukin-10 gene promoter polymorphisms with susceptibility to acute pyelonephritis in children.

Authors:  Juraj Javor; Karol Králinský; Eva Sádová; Oľga Červeňová; Mária Bucová; Michaela Olejárová; Milan Buc; Adriana Liptáková
Journal:  Folia Microbiol (Praha)       Date:  2014-01-22       Impact factor: 2.099

Review 3.  Mechanisms of renal damage owing to infection.

Authors:  Timo Jahnukainen; Ming Chen; Gianni Celsi
Journal:  Pediatr Nephrol       Date:  2005-05-12       Impact factor: 3.714

4.  Roles of interleukin-6 in activation of STAT proteins and recruitment of neutrophils during Escherichia coli pneumonia.

Authors:  Matthew R Jones; Lee J Quinton; Benjamin T Simms; Michal M Lupa; Mariya S Kogan; Joseph P Mizgerd
Journal:  J Infect Dis       Date:  2005-12-27       Impact factor: 5.226

5.  Serum and urine interleukin-6 and transforming growth factor-beta1 in young infants with pyelonephritis.

Authors:  Emmanouil Galanakis; Maria Bitsori; Helen Dimitriou; Christina Giannakopoulou; Nickolaos S Karkavitsas; Maria Kalmanti
Journal:  Int Urol Nephrol       Date:  2007-02-21       Impact factor: 2.370

6.  [Ca2+]i Oscillations and IL-6 Release Induced by α-Hemolysin from Escherichia coli Require P2 Receptor Activation in Renal Epithelia.

Authors:  Mette G Christensen; Steen K Fagerberg; Pauline I de Bruijn; Randi G Bjaelde; Helle Jakobsen; Jens Leipziger; Marianne Skals; Helle A Praetorius
Journal:  J Biol Chem       Date:  2015-04-24       Impact factor: 5.157

7.  Enhanced chemokine response in experimental acute Escherichia coli pyelonephritis in IL-1beta-deficient mice.

Authors:  O Hertting; A Khalil; G Jaremko; M Chromek; Y-H Li; M Bakhiet; T Bartfai; K Tullus; A Brauner
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

8.  Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa.

Authors:  Evangelos J Giamarellos-Bourboulis; Theodoros Adamis; George Laoutaris; Lambros Sabracos; Vassilios Koussoulas; Maria Mouktaroudi; Despina Perrea; Panayotis E Karayannacos; Helen Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

9.  Interleukin-6/Stat3 signaling has an essential role in the host antimicrobial response to urinary tract infection.

Authors:  Christina B Ching; Sudipti Gupta; Birong Li; Hanna Cortado; Nicholas Mayne; Ashley R Jackson; Kirk M McHugh; Brian Becknell
Journal:  Kidney Int       Date:  2018-02-21       Impact factor: 10.612

10.  Trans IL-6 signaling does not appear to play a role in renal scarring after urinary tract infection.

Authors:  Sudipti Gupta; Guillermo Yepes Junquera; Lauren Nicassio; Brian Becknell; Christina B Ching
Journal:  J Pediatr Urol       Date:  2020-05-29       Impact factor: 1.830

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.